Dataset Information

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

ABSTRACT: Cerebral amyloid-? aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid pathology in persons without dementia are needed to understand the development of AD and to design prevention studies.To use individual participant data meta-analysis to estimate the prevalence of amyloid pathology as measured with biomarkers in participants with normal cognition, subjective cognitive impairment (SCI), or mild cognitive impairment (MCI).Relevant biomarker studies identified by searching studies published before April 2015 using the MEDLINE and Web of Science databases and through personal communication with investigators.Studies were included if they provided individual participant data for participants without dementia and used an a priori defined cutoff for amyloid positivity.Individual records were provided for 2914 participants with normal cognition, 697 with SCI, and 3972 with MCI aged 18 to 100 years from 55 studies.Prevalence of amyloid pathology on positron emission tomography or in cerebrospinal fluid according to AD risk factors (age, apolipoprotein E [APOE] genotype, sex, and education) estimated by generalized estimating equations.The prevalence of amyloid pathology increased from age 50 to 90 years from 10% (95% CI, 8%-13%) to 44% (95% CI, 37%-51%) among participants with normal cognition; from 12% (95% CI, 8%-18%) to 43% (95% CI, 32%-55%) among patients with SCI; and from 27% (95% CI, 23%-32%) to 71% (95% CI, 66%-76%) among patients with MCI. APOE-?4 carriers had 2 to 3 times higher prevalence estimates than noncarriers. The age at which 15% of the participants with normal cognition were amyloid positive was approximately 40 years for APOE ?4?4 carriers, 50 years for ?2?4 carriers, 55 years for ?3?4 carriers, 65 years for ?3?3 carriers, and 95 years for ?2?3 carriers. Amyloid positivity was more common in highly educated participants but not associated with sex or biomarker modality.Among persons without dementia, the prevalence of cerebral amyloid pathology as determined by positron emission tomography or cerebrospinal fluid findings was associated with age, APOE genotype, and presence of cognitive impairment. These findings suggest a 20- to 30-year interval between first development of amyloid positivity and onset of dementia.

SUBMITTER: Jansen WJ

PROVIDER: S-EPMC4486209 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

Jansen Willemijn J WJ Ossenkoppele Rik R Knol Dirk L DL Tijms Betty M BM Scheltens Philip P Verhey Frans R J FR Visser Pieter Jelle PJ Aalten Pauline P Aarsland Dag D Alcolea Daniel D Alexander Myriam M Almdahl Ina S IS Arnold Steven E SE Baldeiras Inês I Barthel Henryk H van Berckel Bart N M BN Bibeau Kristen K Blennow Kaj K Brooks David J DJ van Buchem Mark A MA Camus Vincent V Cavedo Enrica E Chen Kewei K Chetelat Gael G Cohen Ann D AD Drzezga Alexander A Engelborghs Sebastiaan S Fagan Anne M AM Fladby Tormod T Fleisher Adam S AS van der Flier Wiesje M WM Ford Lisa L Förster Stefan S Fortea Juan J Foskett Nadia N Frederiksen Kristian S KS Freund-Levi Yvonne Y Frisoni Giovanni B GB Frisoni Giovanni B GB Froelich Lutz L Gabryelewicz Tomasz T Gill Kiran Dip KD Gkatzima Olymbia O Gómez-Tortosa Estrella E Gordon Mark Forrest MF Grimmer Timo T Hampel Harald H Hausner Lucrezia L Hellwig Sabine S Herukka Sanna-Kaisa SK Hildebrandt Helmut H Ishihara Lianna L Ivanoiu Adrian A Jagust William J WJ Johannsen Peter P Kandimalla Ramesh R Kapaki Elisabeth E Klimkowicz-Mrowiec Aleksandra A Klunk William E WE Köhler Sebastian S Koglin Norman N Kornhuber Johannes J Kramberger Milica G MG Van Laere Koen K Landau Susan M SM Lee Dong Young DY de Leon Mony M Lisetti Viviana V Lleó Alberto A Madsen Karine K Maier Wolfgang W Marcusson Jan J Mattsson Niklas N de Mendonça Alexandre A Meulenbroek Olga O Meyer Philipp T PT Mintun Mark A MA Mok Vincent V Molinuevo José Luis JL Møllergård Hanne M HM Morris John C JC Mroczko Barbara B Van der Mussele Stefan S Na Duk L DL Newberg Andrew A Nordberg Agneta A Nordlund Arto A Novak Gerald P GP Paraskevas George P GP Parnetti Lucilla L Perera Gayan G Peters Oliver O Popp Julius J Prabhakar Sudesh S Rabinovici Gil D GD Ramakers Inez H G B IH Rami Lorena L Resende de Oliveira Catarina C Rinne Juha O JO Rodrigue Karen M KM Rodríguez-Rodríguez Eloy E Roe Catherine M CM Rot Uros U Rowe Christopher C CC Rüther Eckart E Sabri Osama O Sanchez-Juan Páscual P Santana Isabel I Sarazin Marie M Schröder Johannes J Schütte Christin C Seo Sang W SW Soetewey Femke F Soininen Hilkka H Spiru Luiza L Struyfs Hanne H Teunissen Charlotte E CE Tsolaki Magda M Vandenberghe Rik R Verbeek Marcel M MM Villemagne Victor L VL Vos Stephanie J B SJ van Waalwijk van Doorn Linda J C LJ Waldemar Gunhild G Wallin Anders A Wallin Åsa K ÅK Wiltfang Jens J Wolk David A DA Zboch Marzena M Zetterberg Henrik H

JAMA 20150501 19

<h4>Importance</h4>Cerebral amyloid-β aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid pathology in persons without dementia are needed to understand the development of AD and to design prevention studies.<h4>Objective</h4>To use individual participant data meta-analysis to estimate the prevalence of amyloid pathology as measured with biomarkers in participants with normal cognition, subjective co ...[more]

PMID: 25988462

Similar Datasets

Project description:Importance:Cerebral amyloid-β aggregation is an early event in Alzheimer disease (AD). Understanding the association between amyloid aggregation and cognitive manifestation in persons without dementia is important for a better understanding of the course of AD and for the design of prevention trials. Objective:To investigate whether amyloid-β aggregation is associated with cognitive functioning in persons without dementia. Design, Setting, and Participants:This cross-sectional study included 2908 participants with normal cognition and 4133 with mild cognitive impairment (MCI) from 53 studies in the multicenter Amyloid Biomarker Study. Normal cognition was defined as having no cognitive concerns for which medical help was sought and scores within the normal range on cognitive tests. Mild cognitive impairment was diagnosed according to published criteria. Study inclusion began in 2013 and is ongoing. Data analysis was performed in January 2017. Main Outcomes and Measures:Global cognitive performance as assessed by the Mini-Mental State Examination (MMSE) and episodic memory performance as assessed by a verbal word learning test. Amyloid aggregation was measured with positron emission tomography or cerebrospinal fluid biomarkers and dichotomized as negative (normal) or positive (abnormal) according to study-specific cutoffs. Generalized estimating equations were used to examine the association between amyloid aggregation and low cognitive scores (MMSE score ≤27 or memory z score≤-1.28) and to assess whether this association was moderated by age, sex, educational level, or apolipoprotein E genotype. Results:Among 2908 persons with normal cognition (mean [SD] age, 67.4 [12.8] years), amyloid positivity was associated with low memory scores after age 70 years (mean difference in amyloid positive vs negative, 4% [95% CI, 0%-7%] at 72 years and 21% [95% CI, 10%-33%] at 90 years) but was not associated with low MMSE scores (mean difference, 3% [95% CI, -1% to 6%], P = .16). Among 4133 patients with MCI (mean [SD] age, 70.2 [8.5] years), amyloid positivity was associated with low memory (mean difference, 16% [95% CI, 12%-20%], P < .001) and low MMSE (mean difference, 14% [95% CI, 12%-17%], P < .001) scores, and this association decreased with age. Low cognitive scores had limited utility for screening of amyloid positivity in persons with normal cognition and those with MCI. In persons with normal cognition, the age-related increase in low memory score paralleled the age-related increase in amyloid positivity with an intervening period of 10 to 15 years. Conclusions and Relevance:Although low memory scores are an early marker of amyloid positivity, their value as a screening measure for early AD among persons without dementia is limited.

Project description:Importance:Brain amyloid deposition is a marker of Alzheimer disease (AD) pathology. The population-based prevalence and outcomes of amyloid positivity in a population without dementia are important for understanding the trajectory of amyloid positivity to clinically significant outcomes and for designing AD prevention trials. Objective:To determine prevalence and outcomes of amyloid positivity in a population without dementia. Design, Setting, and Participants:In the prospective, population-based Mayo Clinic Study of Aging in Olmsted County, Minnesota, participants without dementia were randomly selected from the county population and were clinically and cognitively evaluated at baseline and every 15 months from August 1, 2008, to September 18, 2018. They were also invited to undergo carbon11-Pittburgh compound B positron emission tomography (PET) imaging. Exposures:Amyloid positivity (defined as a standardized uptake value ratio >1.42 on PET). Main Outcomes and Measures:Prevalence of amyloid positivity in the Olmsted County population without dementia and risk of progression from no cognitive impairment (ie, normal cognition for age) to incident amnestic MCI (aMCI) and from MCI or aMCI to incident AD dementia. Results:Of 3894 participants, 1671 underwent PET imaging and were included in the study; 2198 did not undergo imaging, and 25 were excluded for other reasons. The mean (SD) age of participants was 71.3 (9.8) years; 892 (53.4%) were men, and 179 (10.7%) had prevalent MCI. The prevalence of amyloid positivity without cognitive impairment in the population without dementia increased from 2.7% (95% CI, 0.5% to 4.9%) in persons aged 50 to 59 years to 41.3% (95% CI, 33.4% to 49.2%) in those aged 80 to 89 years at baseline. Prevalence of amyloid-positive MCI in the population without dementia increased from 0% in persons aged 50 to 59 years to 16.4% (95% CI, 10.3% to 22.5%) in those aged 80 to 89 years. The incident aMCI risk increased more than 2-fold in participants without cognitive impairment who were amyloid positive vs those who were amyloid negative (hazard ratio [HR], 2.26; 95% CI, 1.52 to 3.35; P < .001). The risk of AD dementia was 1.86 (95% CI, 0.89 to 3.88; P = .10) for amyloid-positive participants with MCI vs amyloid-negative participants with MCI, 1.63 (95% CI, 0.78 to 3.41; P = .20) for participants with aMCI who were amyloid positive vs amyloid negative, and 2.56 (95% CI, 1.35 to 4.88; P = .004) for amyloid-positive participants who were either without cognitive impairment or had aMCI vs those who were amyloid negative. Global cognitive and memory domain z scores declined significantly in amyloid-positive individuals during follow-up. The mean (SD) follow-up time from baseline was 3.7 (1.9) years to incident aMCI and 3.8 (2.0) years to incident AD dementia. Conclusions and Relevance:Population-based prevalence of amyloid-positive status and progression rates of amyloid positivity provide valid information for designing AD prevention trials and assessing the public health outcomes of AD prevention and interventions.

Project description:Amyloid-? positron emission tomography (PET) imaging allows in vivo detection of fibrillar plaques, a core neuropathological feature of Alzheimer disease (AD). Its diagnostic utility is still unclear because amyloid plaques also occur in patients with non-AD dementia.To use individual participant data meta-analysis to estimate the prevalence of amyloid positivity on PET in a wide variety of dementia syndromes.The MEDLINE and Web of Science databases were searched from January 2004 to April 2015 for amyloid PET studies.Case reports and studies on neurological or psychiatric diseases other than dementia were excluded. Corresponding authors of eligible cohorts were invited to provide individual participant data.Data were provided for 1359 participants with clinically diagnosed AD and 538 participants with non-AD dementia. The reference groups were 1849 healthy control participants (based on amyloid PET) and an independent sample of 1369 AD participants (based on autopsy).Estimated prevalence of positive amyloid PET scans according to diagnosis, age, and apolipoprotein E (APOE) ?4 status, using the generalized estimating equations method.The likelihood of amyloid positivity was associated with age and APOE ?4 status. In AD dementia, the prevalence of amyloid positivity decreased from age 50 to 90 years in APOE ?4 noncarriers (86% [95% CI, 73%-94%] at 50 years to 68% [95% CI, 57%-77%] at 90 years; n?=?377) and to a lesser degree in APOE ?4 carriers (97% [95% CI, 92%-99%] at 50 years to 90% [95% CI, 83%-94%] at 90 years; n?=?593; P?<?.01). Similar associations of age and APOE ?4 with amyloid positivity were observed in participants with AD dementia at autopsy. In most non-AD dementias, amyloid positivity increased with both age (from 60 to 80 years) and APOE ?4 carriership (dementia with Lewy bodies: carriers [n?=?16], 63% [95% CI, 48%-80%] at 60 years to 83% [95% CI, 67%-92%] at 80 years; noncarriers [n?=?18], 29% [95% CI, 15%-50%] at 60 years to 54% [95% CI, 30%-77%] at 80 years; frontotemporal dementia: carriers [n?=?48], 19% [95% CI, 12%-28%] at 60 years to 43% [95% CI, 35%-50%] at 80 years; noncarriers [n?=?160], 5% [95% CI, 3%-8%] at 60 years to 14% [95% CI, 11%-18%] at 80 years; vascular dementia: carriers [n?=?30], 25% [95% CI, 9%-52%] at 60 years to 64% [95% CI, 49%-77%] at 80 years; noncarriers [n?=?77], 7% [95% CI, 3%-18%] at 60 years to 29% [95% CI, 17%-43%] at 80 years.Among participants with dementia, the prevalence of amyloid positivity was associated with clinical diagnosis, age, and APOE genotype. These findings indicate the potential clinical utility of amyloid imaging for differential diagnosis in early-onset dementia and to support the clinical diagnosis of participants with AD dementia and noncarrier APOE ?4 status who are older than 70 years.

Project description:Importance:Aging is associated with excessive daytime sleepiness (EDS), which has been linked to cognitive decline in the elderly. However, whether EDS is associated with the pathologic processes of Alzheimer disease remains unclear. Objective:To investigate whether EDS at baseline is associated with a longitudinal increase in regional β-amyloid (Aβ) accumulation in a cohort of elderly individuals without dementia. Design, Setting, and Participants:This prospective analysis included participants enrolled in the Mayo Clinic Study of Aging, a longitudinal population-based study in Olmsted County, Minnesota. Of 2900 participants, 2172 (74.9%) agreed to undergo carbon 11-labeled Pittsburgh compound B positron emission tomography (PiB-PET). We included 283 participants 70 years or older without dementia who completed surveys assessing sleepiness at baseline and had at least 2 consecutive PiB-PET scans from January 1, 2009, through July 31, 2016, after excluding 45 (13.7%) who had a comorbid neurologic disorder. Main Outcomes and Measures:Excessive daytime sleepiness was defined as an Epworth Sleepiness Scale score of at least 10. The difference in Aβ levels between the 2 consecutive scans (ΔPiB) in Aβ-susceptible regions (prefrontal, anterior cingulate, posterior cingulate-precuneus, and parietal) was determined. Multiple linear regression models were fit to explore associations between baseline EDS and ΔPiB while adjusting for baseline age, sex, presence of the apolipoprotein E ε4 allele, educational level, baseline PiB uptake, global PiB positivity (standardized uptake value ratio ≥1.4), physical activity, cardiovascular comorbidities (obesity, hypertension, hyperlipidemia, and diabetes), reduced sleep duration, respiratory symptoms during sleep, depression, and interval between scans. Results:Of the initial 283 participants, mean (SD) age was 77.1 (4.8) years; 204 (72.1%) were men and 79 (27.9%) were women. Sixty-three participants (22.3%) had EDS. Baseline EDS was significantly associated with increased regional Aβ accumulation in the anterior cingulate (B coefficient = 0.031; 95% CI, 0.001-0.061; P = .04), posterior cingulate-precuneus (B coefficient = 0.038; 95% CI, 0.006-0.069; P = .02), and parietal (B coefficient = 0.033; 95% CI, 0.001-0.065; P = .04) regions. Association of EDS with longitudinal Aβ accumulation was stronger in participants with baseline global PiB positivity in the anterior cingulate (B coefficient = 0.065; 95% CI, 0.010-0.118; P = .02) and cingulate-precuneus (B coefficient = 0.068; 95% CI, 0.009-0.126; P = .02) regions. Conclusions and Relevance:Baseline EDS was associated with increased longitudinal Aβ accumulation in elderly persons without dementia, suggesting that those with EDS may be more vulnerable to pathologic changes associated with Alzheimer disease. Further work is needed to elucidate whether EDS is a clinical marker of greater sleep instability, synaptic or network overload, or neurodegeneration of wakefulness-promoting centers. Early identification of patients with EDS and treatment of underlying sleep disorders could reduce Aβ accumulation in this vulnerable group.

Dataset Information

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

Publications

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure